A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer

Published:2013-03-08 Issue:3 Volume:8 Page:e55917
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wang Siying,Peng Liubao,Li Jianhe,Zeng Xiaohui,Ouyang Lihui,Tan Chongqing,Lu Qiong

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference56 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;J Ferlay;Int J Cancer,2010

2. First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer-A Review;YM Chen;J Exp Clin Med,2011

3. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous nonsmall cell lung cancer;G Scagliotti;J Thorac Oncol,2011

4. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;JH Schiller;N Engl J Med,2002

5. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review;J Goffin;J Thorac Oncol,2010

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

2. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

3. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China;PLOS ONE;2023-06-01

4. Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list;BMC Health Services Research;2022-12-03

5. Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China;Frontiers in Public Health;2022-11-03